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Summary
The gene BLM, mutated in Bloom syndrome (BS), en-
codes the nuclear protein BLM, which when absent, as
it is from most BS cells, results in genomic instability.
A manifestation of this instability is an excessive rate
of sister-chromatid exchange (SCE). Here we describe
the effects on this abnormal cellular phenotype of stable
transfection of normal BLM cDNAs into two types of
BS cells, SV40-transformed fibroblasts and Epstein-
Barr virus (EBV)–transformed lymphoblastoid cells.
Clones of BLM-transfected fibroblasts produced nor-
mal amounts of BLM by western blot analysis and
displayed a normal nuclear localization of the protein
by immunofluorescence microscopy. They had a mean
of 24 SCEs/46 chromosomes, in contrast to the mean
of 69 SCEs in controls transfected only with the vector.
BLM-transfected fibroblast clones that expressed high-
est levels of the BLM protein had lowest levels of SCE.
The lymphoblastoid cells transfected with BLM had
SCE frequencies of 22 and 42 in two separate exper-
iments in which two different selectable markers were
used, in contrast to 57 and 58 in vector-transfected
cells; in this type cell, however, the BLM protein was
below the level detectable by western blot analysis.
These experiments prove that BLM cDNA encodes a
functional protein capable of restoring to or toward
normal the uniquely characteristic high-SCE phenotype
of BS cells.
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Introduction
In a recessively transmitted disorder, the abnormal cel-
lular phenotype that is the consequence of the absence
of a normal allele should be corrected by the experi-
mental introduction of the normal allele into mutant
cells. This will be the case provided the normal allele is
expressed and the protein it encodes is produced in ad-
equate amounts.
In recessively transmitted Bloom syndrome (BS [MIM
210900]) (German 1993), a feature of the abnormal so-
matic-cellular phenotype is genomic instability of a
specific type. An important manifestation of the genomic
instability in BS is hyperrecombinability, and an eleva-
tion in the number of sister-chromatid exchanges (SCEs)
is an easily demonstrable—and uniquely diagnos-
tic—cellular phenotype. BLM, the gene mutated in BS,
encodes a 1,417-amino-acid protein that contains a do-
main homologous to the RecQ subfamily of DNA hel-
icases, and RecQ genes have been implicated in cellular
mechanisms that maintain genomic stability. Most of the
∼60 mutations that we have identified in the BLM gene
in individuals with BS result in premature translation
termination of the protein (Ellis et al. 1995; J. German
and N. A. Ellis, unpublished data). Thus, the cellular
phenotype of BS is considered to be the consequence of
the absence of a functional BLM protein. The clinical,
genetic, cytogenetic, and molecular genetic aspects of BS
are reviewed elsewhere (German and Ellis [in press]).
When the BLM gene was isolated (Ellis et al. 1995),
we demonstrated that stable transfection of BLM into
cultured BS cells brought their high-SCE phenotype
toward normal (German et al. 1996). Giesler et al.
(1997) have confirmed this finding. Here, we present
the cytogenetic data more fully. We also show by use
of western blot analysis that the stable transfection
of BLM into SV40-transformed BS fibroblasts results
in expression of BLM protein and by use of immu-
nofluorescence microscopy that BLM localizes to the
nucleus with a distribution resembling that seen in
normal cells. Reduction of SCE was also accomplished
in Epstein-Barr virus (EBV)–transformed BS lympho-
blastoid cells, and in some cells it reached a completely
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normal level; however, for as-yet-unexplained rea-
sons, in that type of cell the BLM protein was not
synthesized to a level that was detected by either west-
ern blot analysis or immunofluorescence.
Material and Methods
Cell Culture
The SV40-transformed fibroblast cell line (FCL)
GM08505 was established at the Coriell Institute for
Medical Research (Camden, NJ) as a permanently
proliferating cell line. This highly aneuploid line,
which maintains the high-SCE phenotype of BS, was
derived from a diploid FCL developed from a skin
biopsy sample obtained from individual 42(RaFr), an
Ashkenazi Jewish woman with BS. 42(RaFr) was ho-
mozygous for the 6-bp deletion and 7-bp insertion
(BLMc.2207-2212delATCTGAinsTAGATTC), a mu-
tation referred to as “blmAsh.” Homozygosity for
blmAsh results in an 80% reduction in the steady-state
levels of BLMmRNA, as determined by means of both
northern analysis and clonal analysis of reverse trans-
criptase–PCR products (N. A. Ellis and T.-Z. Ye, un-
published data), and premature translation termina-
tion at codon 740 in the BLM cDNA (Ellis et al.
1995). For comparison with GM08505 we chose the
permanently proliferating and aneuploid SV40-trans-
formed FCL GM00637, which also was established
at the Coriell Institute but derived from a diploid FCL
developed from a normal adult skin sample.
GM01492 (obtained from the Coriell Institute) is an
FCL developed from a skin biopsy sample of
44(AbRu), a person with BS homozygous for blmAsh.
HG2619 is a diploid FCL developed here from a skin
sample obtained from a normal individual.
HG1525 and HG2703 are near-diploid lympho-
blastoid cell lines (LCLs) established here by EBV
transformation of blood lymphocytes from two in-
dividuals with BS: 81(MaGrou), a French Canadian,
and NR2(CrSpe), an Ashkenazi Jew. HG1525 is ho-
mozygous for mutation BLMc.1784C1A, which
causes a reduction in steady-state BLM mRNA levels
as determined by northern blot analysis and prema-
ture translation termination at codon 595 (authors’
unpublished data); HG2703 is homozygous for
blmAsh. HG2703 was used only in indirect immuno-
fluorescence experiments (see the Immunochemical
Detection of BLM subsection, below). HG2162 and
HG1943 are diploid or near-diploid control LCLs that
were established here from blood drawn from normal
individuals.
The FCLs were cultured in D-MEM medium supple-
mented with 4 mM L-glutamine (Life Technologies) and
10% (v/v) fetal bovine serum (Hyclone). For posttrans-
fection selection, 0.2 mg geneticin/ml (Life Technologies)
was added to the medium. The LCLs were cultured in
RPMI 1640 medium supplemented with 4 mM L-glu-
tamine, 15% (v/v) fetal bovine serum, and 10 mg cip-
rofloxacin/ml (Miles). For posttransfection selection, ei-
ther 0.2 mg hygromycin/ml (Boehringer Mannheim) or
0.3 mg geneticin/ml was added, depending on the se-
lectable marker in the vector being used for the trans-
fection (see the Plasmids subsection, below).
Plasmids
The three cDNAs used for transfection were B3 (the
H1–5′ sequence; GenBank accession number U39817),
R9, and R12 (Ellis et al. 1995). During the present study
R9 and R12 were sequenced by use of dideoxynucleo-
tide-determination reactions.
For transfection of the GM08505 fibroblasts, the in-
tegration/expression vector pOPRSVI-CAT (Stratagene)
was used. DNA from R12 was subcloned by standard
procedures, with BLM being substituted for the CAT
gene in the vector; this construct was named “pOPRSVI-
BLM.” For transfection of the HG1525 lymphoblastoid
cells, the episomal expression vectors pREP4 and pREP9
were used. pREP4 carries the hygr gene, which confers
resistance to hygromycin, and pREP9 carries the neor
gene, which confers resistance to geneticin. R9 and R12
were isolated from a library in which pREP4 is the vector
(Strathdee et al. 1992). DNA from B3 was subcloned
into pREP9; this construct was named “B3R51.” Plas-
mid DNAs were purified by use of Qiagen columns.
Transfection
For fibroblasts, DNAs of the test vector pOPRSVI-
BLM and of the control vector pOPRSVI-CAT were
transfected into GM08505 cells with the use of lipofec-
tamine (Life Technologies) according to the manufac-
turer’s instructions. Thirty-three neor pOPRSVI-BLM
clones and 11 neor pOPRSVI-CAT clones were isolated
and expanded; 8 and 6 of these clones, respectively, were
chosen for further analysis. For lymphoblastoid cells,
each of the two BLM expression constructs R9 and
B3R51 and the vectors pREP4 and pREP9, which were
used as controls, were transfected into HG1525 cells by
electroporation (Ausubel et al. 1999). In brief, a 0.8-ml
suspension of cells was loaded into an ice-cold68# 10
0.4-cm Gene Pulser (Bio-Rad) cuvette; 10 mg of DNA
were then added. The cells and the DNA were held on
ice for 10 min and then electroporated at 330 V and a
capacitance of 960 mF. After another 10 min on ice, the
cells were transferred to a 25-cm2 flask containing 5 ml
nonselective medium and incubated for 4–5 d. The cells
were then transferred to selective medium and cultured
for several weeks. Antibiotic-resistant cultures were ex-
panded for analysis.
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Immunochemical Detection of BLM
Rabbit polyclonal antibodies to an amino-terminal
segment of BLM were raised in a conventional way
(Neff et al. 1999). For western blotting, whole-cell
protein extracts were prepared from pellets of 106–107
cultured cells that were washed once in PBS and frozen
at 70oC. Pellets were resuspended in 100 ml sample
buffer (62.5 mM Tris-HCl pH 6.8, 2% SDS, 0.7 M
b-mercaptoethanol, 10% glycerol, and 0.005% [w/v]
bromophenol blue), the DNA was sheared by passage
through a 26-gauge needle, and the extracts were
boiled for 5 min. Protein concentration was deter-
mined by use of the Bradford method. Thirty micro-
grams of protein per lane were loaded onto an SDS-
polyacrylamide gel, and after electrophoresis immu-
noblots were prepared by standard methods (Harlow
and Lane 1988). After membranes were blocked with
5% nonfat dry milk in PBST (PBS plus 1% Tween-
20) for 1 h, the filters were incubated with unpurified
rabbit polyclonal anti-BLM diluted 1:1,000 in PBST
containing 2% milk for 1 h. After the filters were
washed in PBST, horseradish peroxidase–conjugated
goat anti–rabbit IgG (Vector Laboratories) diluted 1:
5,000 was used as a secondary antibody. For visual-
ization of the conjugated anti-IgG, ECL reagents
(Amersham) were used.
For indirect immunofluorescence, FCLs were cultured
on microscope PLUS slides (Fisher), and LCLs were at-
tached to the slides by use of a Cytospin. Cells were
fixed with equal parts of methanol and acetone for 2
min at room temperature. Preparation of cells for im-
munochemical detection of BLM was by standard pro-
cedures (Harlow and Lane 1988). Normal goat serum
was used to block nonspecific binding. Unpurified rab-
bit anti-BLM diluted 1:500, biotin-conjugated goat
anti–rabbit IgG diluted 1:500, and avidin-conjugated
Texas Red diluted 1:500 in 5 mg 4’6’-diamidino-2-phen-
ylindole (DAPI)/ml were used in successionwithwashing
to detect BLM. Normal goat serum, goat anti–rabbit
IgG, and avidin-conjugated Texas Red were obtained
from Vector Laboratories.
SCE Analysis
The differential staining of sister chromatids in cells
that had replicated their DNA for two cell cycles in bro-
modeoxyuridine employed Hoechst 33258, exposure to
light, and finally Giemsa staining, as described elsewhere
(German et al. 1977). The SCEs in intact metaphases
were enumerated by light microscopy with a 100# ob-
jective. The numbers of SCEs per 46 chromosomes were
determined for both diploid/near-diploid and aneuploid
cell lines.
Results
Western Blot Analysis of Transfected Cells
Two types of BS cells were transfected in these studies,
the SV40-transformed FCL GM08505 and the LCL
HG1525. Both GM08505 and HG1525 were derived
from individuals with BS who were homozygous for pro-
tein-truncating mutations, making these cells effectively
null for BLM and therefore appropriate test recipients
for transfection of normal BLM cDNAs.
The cDNA expression construct used for transfection
of the GM08505 cell line was derived from the R12
cDNA. Its sequence was found to be identical to the
published sequence of the B3 cDNA (Ellis et al. 1995).
Of the two cDNA expression constructs used for trans-
fection of the HG1525 cell line, one was derived from
the B3 cDNA and the other was the R9 cDNA. The
sequences of the B3 and R9 cDNAs contain two amino
acid differences, namely, P868L and V1321L. On the
basis of the data presented here, there is no reason to
suspect that the two proteins produced by these two
cDNAs are not functionally equivalent.
In the normal control SV40-transformed FCL
GM00637, the results of western blot analysis of
whole cell extracts revealed a protein with an appar-
ent molecular weight of 180 kD that was absent from
the SV40-transformed BS GM08505 cells (fig. 1A,
lanes 1 and 2), a finding that proves that it is normal
BLM. Thus, pOPRSVI-BLM encodes a protein with
the same electrophoretic mobility as normal BLM.
This 180-kD protein was expressed at varying levels
in the seven clones that received pOPRSVI-BLM (fig.
1A, lanes 3–9).
In the EBV-transformed LCLs, western blot analyses
demonstrated that the 180-kD protein is present in nor-
mal control lines HG2162 and HG1943 but is absent
from BS line HG1525 (fig. 1B, lanes 1–3). In contrast
to its clear demonstrability in the transfected fibroblasts,
the 180-kD protein was not readily detectable in BS
lymphoblastoid cells transfected with either R9 or B3
(fig. 1B, lanes 4–7; a faint band appeared at the same
position as BLM in BLM-transfected cells but not in
vector-transfected or untransfected cells). We do note
that the LCLs analyzed had not been subcloned, and
variability in the levels of expression of BLM in different
cells in the culture is a possibility. However, according
to the results of immunofluorescence analysis (see the
Nuclear Localization of BLM subsection, below), few,
if any, individual cells exhibited detectable levels of
BLM.
Nuclear Localization of BLM
When BLM antibody is used in indirect immunoflu-
orescence microscopy, most normal control cells contain
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Figure 1 Western blot analysis using rabbit anti-BLM. Whole-
cell protein extract (30 mg) was separated by electrophoresis through
6% SDS polyacrylamide gels. Western blots were prepared with po-
lyvinylidene fluoride membranes, which were probed with rabbit anti-
BLM; immune complexes were visualized with goat anti–rabbit IgG
and the ECL reagent kit (Amersham). A, Analysis of normal, BS, and
BLM-transfected SV40-transformed fibroblasts. Lane 1 represents nor-
mal control GM00637 cells; lane 2, BS GM08505 cells; and lanes 3–9,
pOPRSVI-BLM-transfected clones 13, 34, 41, 42, 43, 44, and 45,
respectively (clone 50 not having been analyzed). B, Analysis of nor-
mal, BS, and BLM-transfected lymphoblastoid cells: Lane 1 represents
normal control HG2162; lane 2, normal control HG1943; lane 3, BS
LCL HG1525; lanes 4–6, B3R51-transfected cells; lane 7, R9-trans-
fected cells; lane 8, control pREP9-transfected cells; and lane 9, control
pREP4-transfected cells. Apparent molecular mass (in kD) is shown.
discrete nuclear foci as well as a diffuse distribution
throughout the nucleus of BLM protein (fig. 2A, C, and
E). Neither the foci nor the diffuse distribution of BLM
is present in cells from most individuals with BS (fig. 2B,
D, and F). Transfection of SV40-transformed BS fibro-
blasts with pOPRSVI-BLM restored both the nuclear
bodies and the diffuse distribution of BLM to the cells
(fig. 2G). As mentioned previously, the BLM-transfected
BS lymphoblastoid cells probed with anti-BLM were in-
distinguishable from untransfected BS lymphoblastoid
cells. We conclude that when BLM expression reaches
a detectable level in transfected cells, the protein assumes
a nuclear organization resembling that in normal cells.
SCE Analysis
In the eight clones of GM08505 BS fibroblasts that
had received pOPRSVI-BLM the mean number of
SCEs per 46 chromosomes was 24, whereas in the six
GM08505 clones that had received pOPRSVI-CAT
the mean number of SCEs per 46 chromosomes was
69 (fig. 3A). The SDs of BLM-transfected GM08505
clones increased with the mean numbers of SCEs, as
did the differences in the high and low values of the
ranges, whereas the SDs and ranges for control CAT-
transfected GM08505 clones were roughly the same
as those for untransfected cells. The three clones that
exhibited the greatest reduction in SCEs were the three
that expressed the highest levels of BLM (compare fig.
1A and fig. 3A).
The mean number of SCEs in the LCL transfectedwith
R9 cDNA was 22, and the mean number of SCEs in the
LCL transfected with B3R51 cDNA was 40 (mean of
three transfection experiments). The means in the con-
trol cultures transfected with the corresponding vectors
were 57 and 58 (fig. 3B). In the R9-transfected cultures,
8 of the 30 cells examined had10 SCEs per metaphase
(i.e., the number of SCEs in diploid cells from normal
individuals), whereas no completely normal–SCE cell
was detected in the B3R51-transfected cultures. The SDs
of BLM-transfected and vector-transfected cultureswere
roughly the same; as expected, the high and low ranges
in the BLM-transfected cultures are reduced compared
with those of the vector-transfected cultures. The re-
duction in SCEs was greater with the hygr-containing
vector (R9) than with the neor-containing vector
(B3R51); however, because the levels of protein in BLM-
transfected HG1525 cells were below the levels that
could be detected by means of either western blot or
immunofluorescence analysis (see the Nuclear Locali-
zation of BLM subsection, above), we could not deter-
mine whether the SCE-reduction difference between vec-
tors was related to a difference in the levels of BLM
expression.
Discussion
In the present study, our primary goal was the cor-
rection of a particularly distinctive abnormal phe-
notype of BS cells, namely, their striking SCE eleva-
tion. Transfection of the cDNA of the gene BLM into
each of two types of BS cells did decrease the mean
SCE frequencies. Furthermore, BLM protein became
demonstrable by western blot analysis in one of the
two cell types transfected, the fibroblasts, and by im-
munofluorescence microscopy BLM was found to
have assumed a nuclear localization and distribution
similar to that of normal (non-BS) fibroblasts. These
experiments constitute proof, independent of earlier
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Figure 2 Indirect immunofluorescence of normal and BS cells stained with polyclonal rabbit anti-BLM antibodies to demonstrate focal
nuclear localization. A, Normal control SV40-transformed FCL GM00637. B, BS SV40-transformed FCL GM08505. C, Normal control FCL
HG2619. D, BS FCL GM01492. E, Normal control LCL HG1943. F, BS LCL HG2703. G, GM08505 clone 34 transfected with pOPRSVI-
BLM.
mutational evidence, that the gene that we have iso-
lated and referred to as “BLM,” is the gene that when
mutated is responsible for BS.
Cells from individuals who are heterozygous for BS-
associated mutations at BLM, that is, the parents of
individuals with BS, have normal SCE rates. Therefore,
successful transfection and expression of at least one
nonmutant BLM allele into a BS cell, even if aneuploid,
was predicted to reduce the SCE rate to the normal
range. Although the mean numbers of SCEs in fibro-
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Figure 3 A, Distribution of SCEs in clones of SV40-transformed
BS fibroblasts (GM08505) transfected with pOPRSVI-BLM or with
the control pOPRSVI-CAT. Normal control GM00637 cells have
SCEs/46 chromosomes, whereas BS GM08505 cells have7 2
SCEs/46 chromosomes. (The average number of chromo-58 16
somes in GM00637 cells was 81, and the average number inGM08505
cells was 82.) Twenty-five metaphases were examined for all lines,
with the exception of CAT clones 49 and 51, in which 20 cells were
analyzed. B, Distribution of SCEs in cultures of BS lymphoblastoid
cells (HG1525) transfected either with BLM (R9 and B3R51) or with
control expression constructs (pREP4 and pREP9). Normal control
HG1943 cells have SCEs per metaphase, whereas BS HG15257 3
cells have SCEs per metaphase. (These cells had 46 chro-69 16
mosomes.) At least 35 metaphases were examined for all lines, with
the exception of B3R51(2) and B3R51(3), in which only 10 cells each
were analyzed.
blasts transfected with BLM were not as low as in the
normal control, they did approach the levels observed
previously by others who had introduced into the same
cells (GM08505) a normal BLM gene in situ in chro-
mosome 15 (McDaniel and Schultz 1992). In our ex-
periments, those clones of BLM-transfected fibroblasts
that expressed the highest levels of protein exhibited the
lowest mean SCE rate (fig. 1A and fig. 3A). These ob-
servations from different laboratories suggest that, for
currently obscure reasons, the SCE reduction is as low
as can be expected in experiments in which the aneuploid
SV40-transformed GM08505 cells are the test recipient.
By this argument, the SCE reduction observed in our
experiments represents full correction of the high-SCE
phenotype of GM08505 cells.
With respect to near-diploid EBV-transformed lym-
phoblastoid cells, transfection of the HG1525 cells with
the different BLM cDNAs, R9 and B3R51, resulted in
different mean numbers of SCEs (fig. 3B). Some fully
corrected cells (!10 SCEs per metaphase) were found in
the R9-transfected but not in the B3R51-transfected cul-
tures; however, cultures transfected with both these
cDNAs contained cells with either an intermediate- or
a high-SCE phenotype. Sequence differences betweenR9
and B3R51 fail to explain the difference in SCE reduc-
tion, for they encode identical proteins. In addition, the
low level of BLM expression in the lymphoblastoid
transfectants determined by western blot analysis is puz-
zling (fig. 1B). To explain the cells with normal numbers
of SCEs, we postulate that BLM expression in some of
the R9-transfected lymphoblastoid cells is sufficient to
provide full correction but that in others it falls short,
and there an intermediate- or even high-SCE phenotype
persists. By this interpretation, the cells in the R9-trans-
fected cultures (hygr) in aggregate would be expressing
more BLM than those in the B3R51-transfected cultures
(neor).
The experiments reported fulfill the prediction made
in the first paragraph of our Introduction. Now, with
the successful transfection of BLM into BS cells and cor-
rection of the marker-phenotype SCE elevation, the way
lies open for structure-function experiments employing
variously mutated BLM genes. Transfection of BLM
cDNA constructs experimentally altered to encode pro-
teins with specific amino acid substitutions and deletions
will help determine the portions of the protein that are
required both for BLM’s characteristic nuclear distri-
bution and for its colocalization with other nuclear pro-
teins at certain periods of the cell cycle (observations to
be reported), thence an understanding of the function(s)
of BLM in chromosome mechanics and DNA metabo-
lism. The work possibly deserves extension to untrans-
formed diploid BS cells with a view toward examination
of the feasibility of gene therapy for BS.
Finally, the experience gained in this work indicates
that the SCE assay remains the most reliable test avail-
able for the presence of a normal allele at the BS locus,
specifically an allele that is being transcribed and from
which a functional BLM protein is produced.
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